A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
-
ORGANIZATION Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
-
BUSINESS AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
-
REGULATORY LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
-
REGULATORY MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
-
ORGANIZATION Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
-
BUSINESS AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
-
REGULATORY Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
-
REGULATORY Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
June 8, 2023
-
REGULATORY Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
-
REGULATORY Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
-
ORGANIZATION Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
-
BUSINESS Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
-
REGULATORY Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
-
REGULATORY Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
-
BUSINESS Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
-
BUSINESS Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
-
BUSINESS AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
-
REGULATORY Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
-
REGULATORY MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…